STAT
FEBRUARY 16, 2024
Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.
ALiEM - Pharm Pearls
FEBRUARY 16, 2024
An 86-year-old man with a past medical history of coronary artery disease, hypertension, hyperlipidemia, chronic kidney disease, COPD, choledocholithiasis requiring ERCP and sphincterotomy 2 years ago presented with five days of feeling unwell. History was limited due to cognitive impairment. His daughter had reported to staff he had been feeling unwell for five days, intermittently having nausea and generalized abdominal pain, subjective fevers, chest pain, and shortness of breath.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
FEBRUARY 16, 2024
Two days after his right hand froze, Hart Bezner realized for the first time that he might lose it. The retired physics professor was sitting in an emergency room in Whitehorse, the capital of Canada’s Yukon territory, where two doctors and a pharmacist were taking an unusual amount of interest in the appendage and the pink blisters that now covered it.
PharmaVoice
FEBRUARY 16, 2024
Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
FEBRUARY 16, 2024
Space is famously known as the final frontier for human exploration. It may also be the final frontier for human medicine. That’s what Dorit Donoviel, executive director of the Translational Research Institute for Space Health, and her team are working towards. TRISH is a consortium between Baylor College of Medicine, Caltech, and the Massachusetts Institute of Technology that partners with NASA to solve the health challenges of humans exploring deep space.
The Pharmacist
FEBRUARY 16, 2024
Hundreds of community pharmacies have begun offering a tirzepatide injection as part of a new weight loss service beginning this week. The move follows the approval of a new four-dose version of Mounjaro last month. It is hoped that the new service will expand the availability of private weight-loss treatments amid ongoing shortages of alternatives […] The post Mounjaro weight loss service hoped to ease supply issues appeared first on The Pharmacist.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
pharmaphorum
FEBRUARY 16, 2024
CAR-T therapies can achieve remarkable efficacy in the treatment of haematological cancers, but the risk of side effects means that the cell infusions are almost always administered to inpatients under close supervision in clinics.
STAT
FEBRUARY 16, 2024
NEW YORK — Smoking has surpassed injecting as the most common way of taking drugs in U.S. overdose deaths, a new government study suggests. The Centers for Disease Control and Prevention called its study published Thursday the largest to look at how Americans took the drugs that killed them.
pharmaphorum
FEBRUARY 16, 2024
Recent biotech financings include a $245m raise for cancer blood test company Freenome, plus big rounds for Cogent Biosciences, BioAge Labs, Latigo Biotherapeutics, ProfoundBio, and Firefly Bio
STAT
FEBRUARY 16, 2024
Prominent immunologist and oncologist Padmanee Sharma defended herself in court on Friday against a lawsuit that alleges she threatened to undermine a junior faculty member’s career, made defamatory comments about the younger scientist, and attempted to take credit for work that she didn’t do. In legal filings submitted to the Harris County District Court, Sharma said that she made substantial contributions to an immunotherapy project that were ignored, and that a third-party asses
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Express Pharma
FEBRUARY 16, 2024
As part of the collaboration with IISc, BFI-Biome Network will allocate up to $1 million over three years to drive its Translational Research Projects ranging from TRL 2-4 Blockchain for Impact, the philanthropy initiative by Sandeep Nailwal, has announced a $15 million fund dedicated to advancing biomedical research and innovation in India, under the BFI-Biome Virtual network.
STAT
FEBRUARY 16, 2024
Sonata Therapeutics, a startup created two years ago through the merger of two Flagship Pioneering companies, has laid off about a third of its staff. The biotech laid off 21 employees in recent weeks, according to employee posts on social media and a company spokesperson. Sonata had around 63 employees before the layoffs. Sonata is just the latest in a series of startups laying off employees in order to stretch out their cash runways.
pharmaphorum
FEBRUARY 16, 2024
Gilead Sciences has paused enrolment in clinical trials of its CD47 drug magrolimab in solid tumours, a week after dropping it for blood cancers.
STAT
FEBRUARY 16, 2024
A deal is never really done until it’s done. On Tuesday, two different proposed insurance plan acquisitions on different sides of the country called it quits — one of them for the second time. California-based Medicare Advantage insurer SCAN Group has been trying to buy CareOregon, an insurer offering coverage to half a million people in Oregon’s state health plan, since January 2023.
The Pharmacist
FEBRUARY 16, 2024
EXCLUSIVE Community pharmacy needs a ‘new deal’ that considers estates costs, training time and does not force pharmacies to dispense at a loss, the recently appointed National Pharmacy Association (NPA) chief executive has told The Pharmacist. In his first interview with The Pharmacist since his appointment in November, Paul Rees spoke about his experience working […] The post Paul Rees: ‘We need a new deal for pharmacy’ appeared first on The Pharmacist.
STAT
FEBRUARY 16, 2024
CAMBRIDGE, Mass. — The increasingly adversarial relationship between the United States and China has raised national security concerns about Chinese penetration into key sectors of the U.S. economy, such as technology, manufacturing, and clean energy. Now, some in Congress are raising alarms about China’s threat to another vital industry: biotechnology.
pharmaphorum
FEBRUARY 16, 2024
Astellas has signed a deal with Kelonia Therapeutics that aims to push the boundaries of what can be achieved with CAR-T therapies in immuno-oncology
STAT
FEBRUARY 16, 2024
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we expect to promenade with the official mascots, check in on the Pharmalot ancestors, and hold another listening party, where the rotation will likely include this , this , this , this and this.
BioPharma Dive
FEBRUARY 16, 2024
The disclosure the experimental therapy missed its trial goal comes after Sanofi had earmarked the drug for advancement into Phase 3.
STAT
FEBRUARY 16, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at pharma’s struggle to make inroads in D.C., the curious story of the latest FDA drug approval, and a twist on the year’s biggest biotech event. One more thing: We’ll be taking off Monday for Presidents’ Day, but this newsletter will be back in your inbox bright and early Tuesday morning.
pharmaphorum
FEBRUARY 16, 2024
The ABPI has released a new guide on how the industry can support clinicians with prescribing decisions. Find out more about how pharmaceutical companies can assist healthcare professionals in providing optimal patient care.
STAT
FEBRUARY 16, 2024
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
BioPharma Dive
FEBRUARY 16, 2024
Kelonia will receive $40 million upfront through a partnership to develop “off-the-shelf” cell therapies for cancer.
pharmaphorum
FEBRUARY 16, 2024
Explore the role of artificial intelligence and machine learning in drug discovery and the challenges associated with patentability and predictability. Learn how AI is revolutionising the pharmaceutical industry.
Digital Pharmacist
FEBRUARY 16, 2024
In an age where technology is advancing at an exponential rate, it’s no surprise that traditional methods of communication are gradually being phased out. One such example is the shift away from copper wire landline services, a move that has been gaining momentum across various regions in the United States. This transition signifies a significant shift towards a more modern and efficient telecommunications infrastructure, but as with any change, is sure to be accompanied by some challenges
pharmaphorum
FEBRUARY 16, 2024
Patterns of behaviour: Using AI-based algorithms to improve outcomes for patients with atrial fibrillation Mike.
Pharmaceutical Technology
FEBRUARY 16, 2024
This positive news comes after Otsuka’s Phase III Alzheimer’s agitation trial failed to meet its primary endpoint, announced earlier this week.
pharmaphorum
FEBRUARY 16, 2024
In this interview, Jonah Comstock speaks with Xavier Duportet, the founder and CEO of the biotech company, Eligo Bioscience, about the future of CRISPR gene editing at JP Morgan in 2024. Dive into the discussion to gain insights into this cutting-edge technology and its potential impact on the healthcare industry.
Pharma Times
FEBRUARY 16, 2024
Cardiac quantitative susceptibility mapping successfully visualised iron deposits in patients
Drug Channels
FEBRUARY 16, 2024
Today’s guest post comes from Gavin Magaha, Senior Director of Value Delivery at Kalderos. Gavin discusses the problems manufacturers face in accessing and standardizing drug discount data. These data are necessary to avoid duplicate discounts and comply with regulatory requirements. To learn more about how the Inflation Reduction Act adds to challenges of drug discount programs, download Kalderos’ whitepaper: Operational Complexity and Evolving Challenges: What Drug Manufacturers Need to Know N
Pharmaceutical Technology
FEBRUARY 16, 2024
GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, expanding its respiratory portfolio.
European Pharmaceutical Review
FEBRUARY 16, 2024
Researchers have highlighted the potential of end-to-end continuous manufacture with column-free capture alternatives. The traditional batch process was compared with end-to-end continuous bioprocesses with either protein A (ProA) capture or column-free capture, employing aqueous two-phase extraction (ATPE) or precipitation from economic, environmental, and robustness perspectives.
Pharma Times
FEBRUARY 16, 2024
NRTX-1001 is being assessed for drug-resistant mesial temporal lobe epilepsy
Pharmaceutical Commerce
FEBRUARY 16, 2024
The financial commitment features construction of new warehouses in Pennsylvania and North Carolina.
World Pharma News
FEBRUARY 16, 2024
Scientists at the University of Illinois Chicago and Harvard University have developed an antibiotic that could give medicine a new weapon to fight drug-resistant bacteria and the diseases they cause. The antibiotic, cresomycin, described in Science, effectively suppresses pathogenic bacteria that have become resistant to many commonly prescribed antimicrobial drugs.
Expert insights. Personalized for you.
356 
Let's personalize your content